Evidence map›Paper›PMID 40458962›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community.

Rachael M Crist, Yechezkel Barenholz, Ahuva Cern, Kate N Clark, Pieter R Cullis, Cheryl Dean, Neil Desai, Mauro Ferrari, Matthieu Germain, Carmen A Giacomantonio and 20 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Rachael M CristNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.ORCID 0000-0002-3299-4842
Yechezkel BarenholzLaboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Ahuva CernLaboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Kate N ClarkDepartment of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Pieter R CullisDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-9586-2508
Cheryl DeanDepartment of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Neil DesaiAanastra, Los Angeles, California, USA.
Mauro FerrariDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Matthieu GermainNanobiotix, Paris, France.
Carmen A GiacomantonioDepartment of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Emma GrabarnikNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Piotr GrodzinskiNanodelivery Systems and Devices Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-2245-9870
Atara HodLaboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Barry E KennedyDepartment of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Ruvanthi N KularatneNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.ORCID 0000-0002-6916-2011
Glen S KwonPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Emmanuel LoebPatho-Logica, Ness Ziona, Israel.
Erin B NoftallDepartment of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Len PagliaroDepartment of R&D, Sona Nanotech, Inc., Halifax, Nova Scotia, Canada.
Morteza RasoulianboroujeniPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alexander RothDepartment of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Darren RowlesDepartment of R&D, Sona Nanotech, Inc., Halifax, Nova Scotia, Canada.
Kulbir SinghDepartment of R&D, Sona Nanotech, Inc., Halifax, Nova Scotia, Canada.
Nicole F SteinmetzAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, California, USA.ORCID 0000-0002-0130-0481
Zhanna YehtinaLaboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Yao ZhangDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-2783-1317
Daniel ZilbersheidLaboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Jeffrey D ClogstonNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.ORCID 0009-0003-6150-3904
Stephan T SternNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · 2019 to 2025
$3932.6M
Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
Toward translation of a plant virus-based in situ vaccination nanotechnologyR01CA274640 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, RANJAN, ASHISH · 2022 to 2025
$2.5M
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination TherapyR01CA257837 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KWON, GLEN S. · 2021 to 2024
$1.4M
American Cancer Society - F.M. Kirby Foundation Inc. - Mission Boost Grant MBGI-23-1030244-01-MBGCanadian Institutes for Health Research FDN 148469Canadian Institutes of Health Research Doctoral Award FBD 193487DOD Breast Cancer Research Program W81XWH1710389NCI NIH HHS 75N91019D00024NCI NIH HHS R01 CA257837NIH HHS R01 CA224605NIH HHS R01 CA253615NIH HHS R01 CA274640
6 · The paper itself

Abstract

The Nanotechnology Characterization Laboratory (NCL) is a US federally funded resource providing characterization and expertise to the cancer nanomedicine research community. Founded as a formal partnership among the US National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and the US National Institute of Standards and Technology (NIST), the NCL has spent two decades developing a one-of-a-kind service with broad multidisciplinary expertise to meet the needs of a rapidly evolving drug development field. To mark the 20th anniversary of the lab's founding, the NCL hosted a symposium to highlight the achievements of the cancer nanomedicine field, showcase novel, next-generation nanotechnology research, and discuss future priorities to enable continued growth in combating cancer and the complexities associated with treating a disease that continues to take millions of lives annually. The discussion topics from this event are summarized.

Indexed as

NanomedicineNanotechnologyNational Cancer Institute (U.S.)NeoplasmsHumansUnited Statescancernanomedicinenanotechnology

Identifiers

PMID40458962
PMCPMC12131291

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.